ATE286725T1 - Neue oral anzuwendende arzneizubereitungen für rivastigmine mit kontrollierter wirkstoffabgabe - Google Patents

Neue oral anzuwendende arzneizubereitungen für rivastigmine mit kontrollierter wirkstoffabgabe

Info

Publication number
ATE286725T1
ATE286725T1 AT99950595T AT99950595T ATE286725T1 AT E286725 T1 ATE286725 T1 AT E286725T1 AT 99950595 T AT99950595 T AT 99950595T AT 99950595 T AT99950595 T AT 99950595T AT E286725 T1 ATE286725 T1 AT E286725T1
Authority
AT
Austria
Prior art keywords
rivastigmine
active ingredients
controlled release
medicinal preparations
new oral
Prior art date
Application number
AT99950595T
Other languages
English (en)
Inventor
Joerg Ogorka
Oskar Kalb
Rajen Shah
Satish Chandra Khanna
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27547321&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE286725(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9821299.6A external-priority patent/GB9821299D0/en
Priority claimed from GBGB9821298.8A external-priority patent/GB9821298D0/en
Priority claimed from GBGB9826654.7A external-priority patent/GB9826654D0/en
Priority claimed from GBGB9827624.9A external-priority patent/GB9827624D0/en
Priority claimed from GBGB9907822.2A external-priority patent/GB9907822D0/en
Priority claimed from GBGB9907823.0A external-priority patent/GB9907823D0/en
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE286725T1 publication Critical patent/ATE286725T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT99950595T 1998-10-01 1999-10-01 Neue oral anzuwendende arzneizubereitungen für rivastigmine mit kontrollierter wirkstoffabgabe ATE286725T1 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB9821299.6A GB9821299D0 (en) 1998-10-01 1998-10-01 Organic compounds
GBGB9821298.8A GB9821298D0 (en) 1998-10-01 1998-10-01 Organic compoundsq
GBGB9826654.7A GB9826654D0 (en) 1998-12-03 1998-12-03 Organic compounds
GBGB9827624.9A GB9827624D0 (en) 1998-12-16 1998-12-16 Organic compounds
GBGB9907822.2A GB9907822D0 (en) 1999-04-06 1999-04-06 Organic compounds
GBGB9907823.0A GB9907823D0 (en) 1999-04-06 1999-04-06 Organic compounds
PCT/EP1999/007298 WO2000019985A2 (en) 1998-10-01 1999-10-01 New sustained release oral formulations

Publications (1)

Publication Number Publication Date
ATE286725T1 true ATE286725T1 (de) 2005-01-15

Family

ID=27547321

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99950595T ATE286725T1 (de) 1998-10-01 1999-10-01 Neue oral anzuwendende arzneizubereitungen für rivastigmine mit kontrollierter wirkstoffabgabe

Country Status (23)

Country Link
US (5) US20010033866A1 (de)
EP (1) EP1121104B1 (de)
JP (1) JP4012689B2 (de)
KR (1) KR100603900B1 (de)
CN (1) CN1406126A (de)
AT (1) ATE286725T1 (de)
AU (1) AU764866B2 (de)
BR (1) BR9914251A (de)
CA (1) CA2342340C (de)
CZ (1) CZ302888B6 (de)
DE (1) DE69923200T2 (de)
ES (1) ES2237163T3 (de)
HK (1) HK1052473A1 (de)
HU (1) HUP0103883A3 (de)
ID (1) ID27504A (de)
IL (2) IL141762A0 (de)
NO (1) NO331689B1 (de)
NZ (1) NZ510683A (de)
PL (1) PL196945B1 (de)
PT (1) PT1121104E (de)
SK (1) SK285250B6 (de)
TR (1) TR200100931T2 (de)
WO (1) WO2000019985A2 (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9914251A (pt) * 1998-10-01 2001-06-19 Novartis Ag Formulações orais de liberação sustentada
WO2000030446A1 (en) * 1998-11-23 2000-06-02 Bonnie Davis Dosage formulations for acetylcholinesterase inhibitors
CA2380333A1 (en) * 1999-08-26 2001-03-01 Christian Andina Pharmaceutical formulations
GB9923045D0 (en) * 1999-09-29 1999-12-01 Novartis Ag New oral formulations
AU2357202A (en) * 2000-09-29 2002-04-08 Solvay Pharm Bv Ion-strength independent sustained release pharmaceutical formulation
JP5023412B2 (ja) * 2001-05-09 2012-09-12 吉澤石灰工業株式会社 ホルムアルデヒド廃液の処理剤
JP2005525299A (ja) * 2001-09-14 2005-08-25 スコラー インコーポレイテッド アミノ酸調節性の長期放出投薬形態
DE60223695T2 (de) * 2001-09-14 2008-10-30 Scolr, Inc., Redmond Aminosäure-modulierte dosierform mit verlängerter freisetzung
KR100453288B1 (ko) * 2002-03-12 2004-10-21 한국화학연구원 약물의 제어 방출을 위한 스퀴즈-유형의 삼투성 약물 전달장치
ES2327914T3 (es) * 2002-08-07 2009-11-05 Novartis Ag Metodo para pronosticar la sensibilidad al tratamiento con ravastigmina basado en el genotipo apoe de pacintes con demencia.
ZA200508653B (en) * 2003-04-07 2007-03-28 Jurox Pty Ltd Stable carprofen composition
WO2004100929A1 (en) * 2003-05-12 2004-11-25 Synergia Pharma, Inc. Threo-dops controlled release formulation
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
ME00391B (me) * 2003-08-08 2011-10-10 Biovail Laboratories Int Srl Tableta bupropion hidrohlorida sa modifikovanim otpuštanjem
US20100129310A1 (en) * 2004-08-09 2010-05-27 Pavak Rajnikanth Mehta Stabilized desloratadine composition
US8431156B2 (en) * 2005-02-22 2013-04-30 Sun Pharma Advanced Research Company Ltd. Pharmaceutical composition
US20060264458A1 (en) * 2005-05-03 2006-11-23 Jie Du Quinine dosage forms and methods of use thereof
CA2620594C (en) * 2005-09-01 2012-08-21 Eisai R&D Management Co., Ltd. Pharmaceutical composition having improved disintegratability
GB0525461D0 (en) * 2005-12-15 2006-01-25 Archimedes Dev Ltd Pharmaceutical compositions
GB0606562D0 (en) * 2006-03-31 2006-05-10 Novartis Ag Organic compounds
JP5230613B2 (ja) 2006-05-23 2013-07-10 テラコス・インコーポレイテッド グルコース輸送体阻害剤およびその使用方法
US7893053B2 (en) 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
US8748419B2 (en) 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
BRPI0809607A2 (pt) 2007-04-02 2014-09-30 Theracos Inc Composto, composição farmacêutica, combinação farmacêutica, e, método para tratar uma doença
ITMI20071502A1 (it) * 2007-07-25 2009-01-26 Archimica Srl Procedimento per la preparazione di formulazioni solide a rilascio controllato contenenti oxcarbazepina e formulazioni ottenibili con tale procedimento
WO2009022345A1 (en) * 2007-08-14 2009-02-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Phenyl carbamates for the treatment of multiple sclerosis
MX2010002027A (es) 2007-08-23 2010-03-15 Theracos Inc Derivados de bencilbenceno y metodos de uso.
WO2009042625A1 (en) * 2007-09-25 2009-04-02 Idexx Laboratories, Inc. Pharmaceutical compositions for administering oligonucleotides
US20110201597A1 (en) 2008-03-27 2011-08-18 Chase Thomas N Method and composition for treating alzheimer-type dementia
FR2931677B1 (fr) * 2008-06-02 2010-08-20 Sanofi Aventis Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs
AU2009270936B2 (en) 2008-07-15 2014-12-18 Theracos, Inc. Deuterated benzylbenzene derivatives and methods of use
MX2011001855A (es) 2008-08-22 2011-03-24 Theracos Inc Procesos para la preparacion de inhibidores de sglt2.
CA2744498C (en) 2008-11-25 2017-10-24 University Of Rochester Mlk inhibitors and methods of use
MX345236B (es) * 2009-09-18 2017-01-23 Chase Pharmaceuticals Corp Metodo y composicion para tratar la demencia de tipo alzheimer.
US20110150986A1 (en) * 2009-12-18 2011-06-23 Kristin Arnold Quinine formulations, method of making, and metho of use thereof
CN101797236B (zh) * 2010-03-23 2012-05-23 西南大学 重酒石酸卡巴拉汀口腔崩解片及其制备方法
AU2011258465B2 (en) 2010-05-24 2016-12-15 University Of Rochester Bicyclic heteroaryl kinase inhibitors and methods of use
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
JP6133790B2 (ja) 2011-02-18 2017-05-24 ザ スクリプス リサーチ インスティテュート ミエリン形成細胞運命へのオリゴデンドロサイト前駆細胞の定方向分化
CN103402519B (zh) 2011-04-18 2015-11-25 卫材R&D管理有限公司 肿瘤治疗剂
US20140065213A1 (en) * 2011-05-06 2014-03-06 GlaxoSmithKline, LLC Sustained Release Paracetamol Formulations
KR102158948B1 (ko) 2011-05-13 2020-09-24 이비 아이피 하이브리탭스 비.브이. 약물 전달 시스템
US8524664B2 (en) 2011-06-02 2013-09-03 Colorado Seminary, Which owns and Operates The Univeristy of Denver Methods of treating overproduction of cortisol using ACTH antagonist peptides
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
KR102035877B1 (ko) 2011-11-14 2019-10-23 알파시그마 에스.피.에이. 우울증이 있는 대상체를 위한 치료 양생법 선택을 위한 검정법 및 치료 방법
EP4035668A1 (de) 2012-09-05 2022-08-03 Chase Pharmaceuticals Corporation Neuroprotektive anticholinergische zusammensetzung und verfahren
EP2925319B1 (de) 2012-11-30 2019-01-09 University Of Rochester Mixed-lineage-kinaseinhibitoren für hiv/aids-therapien
AU2013364953A1 (en) 2012-12-21 2015-04-30 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
EP2997377B1 (de) 2013-05-14 2018-07-18 Eisai R&D Management Co., Ltd. Biomarker zur vorhersage und beurteilung der reaktion von endometriumkarzinompatienten auf lenvatinibverbindungen
AU2014307803A1 (en) 2013-08-16 2016-03-10 Universiteit Maastricht Treatment of cognitive impairment with PDE4 inhibitor
WO2015136446A1 (en) 2014-03-11 2015-09-17 Nestec S.A. Methods for selecting antidepressant drug therapy to treat depression
CN103877063A (zh) * 2014-03-24 2014-06-25 张绪伟 一种重酒石酸卡巴拉汀胶囊及其制备方法
PT3524595T (pt) 2014-08-28 2022-09-19 Eisai R&D Man Co Ltd Derivado de quinolina altamente puro e método para produção do mesmo
AU2016224583B2 (en) 2015-02-25 2021-06-03 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
KR101990951B1 (ko) * 2015-04-27 2019-06-20 주식회사 네비팜 리바스티그민 함유 서방출 의약조성물
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
JP6553726B2 (ja) 2015-08-20 2019-07-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
IL243707A0 (en) 2016-01-20 2016-05-01 Galmed Res And Dev Ltd Treatment to regulate the microbiota in the intestine
JP6581320B2 (ja) 2017-02-08 2019-09-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
EP3624800A4 (de) 2017-05-16 2021-02-17 Eisai R&D Management Co., Ltd. Behandlung von leberzellkarzinom
KR20190021180A (ko) * 2017-08-22 2019-03-05 아주대학교산학협력단 퇴행성 신경질환 치료용 복합 제형 조성물
KR20190036370A (ko) 2017-09-27 2019-04-04 서원대학교산학협력단 약물의 서방성 제형을 위한 약물전달체
SMT202400056T1 (it) * 2018-07-30 2024-03-13 Biothea Pharma Inc Sale cristallino di malonato di epinefrina
CN112546037A (zh) * 2020-12-08 2021-03-26 苏州大学 卡巴拉汀在制备抗辐射药中的应用
CN113398273B (zh) * 2021-05-14 2022-07-19 广西壮族自治区中国科学院广西植物研究所 木聚糖衍生物作为亲水性缓释材料在制备药物缓释片中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4014335A (en) * 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
USRE34990E (en) * 1986-08-07 1995-07-04 Ciba-Geigy Corporation Oral therapeutic system having systemic action
HU201906B (en) 1987-03-04 1991-01-28 Sandoz Ag Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them
DE3805744C2 (de) * 1987-03-04 1999-09-23 Novartis Ag Phenylcarbamate zur Hemmung der Acetylcholinesterase
DE3922167A1 (de) * 1988-04-16 1991-01-17 Sanol Arznei Schwarz Gmbh Oral zu verabreichende diltiazemhydrochlorid enthaltende pharmazeutische zubereitung zur einmal taeglichen applikation und verfahren zu deren herstellung
US5472710A (en) * 1988-04-16 1995-12-05 Schwarz Pharma Ag Pharmaceutical preparation to be administered orally with controlled release of active substance and method for its manufacture
US5262173A (en) * 1992-03-02 1993-11-16 American Cyanamid Company Pulsatile once-a-day delivery systems for minocycline
US5260068A (en) * 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
ATE195252T1 (de) * 1993-04-23 2000-08-15 Novartis Erfind Verwalt Gmbh Wirkstoffabgabevorrichtung mit gesteuerter freigabe
US5698224A (en) * 1994-06-27 1997-12-16 Alza Corporation Tacrine therapy
US5962535A (en) * 1997-01-17 1999-10-05 Takeda Chemical Industries, Ltd. Composition for alzheimer's disease
GB9701695D0 (en) 1997-01-28 1997-03-19 De Beers Ind Diamond Insert for an abrasive tool
DE19707655A1 (de) * 1997-02-26 1998-08-27 Hoechst Ag Kombinationspräparat zur Anwendung bei Demenz
IL128043A (en) * 1997-05-30 2004-08-31 Osmotica Corp Multi-layered osmotic device for controlled delivery of active agents
GB9800526D0 (en) * 1998-01-12 1998-03-11 Ciba Geigy Ag Organic compounds
BR9914251A (pt) * 1998-10-01 2001-06-19 Novartis Ag Formulações orais de liberação sustentada
US6534541B1 (en) 1999-10-19 2003-03-18 Novartis Ag Treatment of ocular disorders

Also Published As

Publication number Publication date
CN1406126A (zh) 2003-03-26
AU764866B2 (en) 2003-09-04
ID27504A (id) 2001-04-12
IL141762A0 (en) 2002-03-10
US20010033866A1 (en) 2001-10-25
HK1052473A1 (zh) 2003-09-19
EP1121104A2 (de) 2001-08-08
SK285250B6 (sk) 2006-09-07
PL196945B1 (pl) 2008-02-29
HUP0103883A2 (hu) 2002-05-29
US20070053982A1 (en) 2007-03-08
SK4392001A3 (en) 2002-07-02
CZ302888B6 (cs) 2012-01-11
DE69923200T2 (de) 2005-12-22
NO331689B1 (no) 2012-02-27
BR9914251A (pt) 2001-06-19
NZ510683A (en) 2003-09-26
PL348734A1 (en) 2002-06-03
AU6332199A (en) 2000-04-26
CZ20011155A3 (cs) 2001-08-15
TR200100931T2 (tr) 2001-10-22
ES2237163T3 (es) 2005-07-16
JP2002526402A (ja) 2002-08-20
NO20011471D0 (no) 2001-03-22
JP4012689B2 (ja) 2007-11-21
CA2342340A1 (en) 2000-04-13
US6565883B2 (en) 2003-05-20
WO2000019985A2 (en) 2000-04-13
US20030039692A1 (en) 2003-02-27
KR20010073168A (ko) 2001-07-31
IL141762A (en) 2010-06-30
US20030203025A1 (en) 2003-10-30
PT1121104E (pt) 2005-05-31
DE69923200D1 (de) 2005-02-17
US20050175706A1 (en) 2005-08-11
NO20011471L (no) 2001-03-22
KR100603900B1 (ko) 2006-07-25
CA2342340C (en) 2006-08-29
EP1121104B1 (de) 2005-01-12
HUP0103883A3 (en) 2002-11-28
WO2000019985A3 (en) 2000-07-20

Similar Documents

Publication Publication Date Title
ATE286725T1 (de) Neue oral anzuwendende arzneizubereitungen für rivastigmine mit kontrollierter wirkstoffabgabe
HRP20070188B1 (hr) Farmaceutska kombinacija etinilestradiola i drospirenona za upotrebu kao kontracepcijskog sredstva
BRPI0015567B8 (pt) composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica
GB0007419D0 (en) Composition
ES2061591T3 (es) Administracion intranasal de polipeptidos en forma pulverizada.
PT1035834E (pt) Forma de dosagem osmotica que compreende primeiro e segundo revestimentos
DK196189D0 (da) Oralt osmotisk dispenseringssystem indeholdende et farmakologisk aktivt stof
DE69434121D1 (de) Pharmazeutische zusammensetzung zur immunstimulierenden therapie
DE60019334D1 (de) Antivirale arznei
AP2003002763A0 (en) Controlled release formulations for oral administration
DE59907481D1 (de) Kontrolliert freisetzende pharmazeutische zusammensetzung mit tilidinmesylat als wirkstoff
GB9814215D0 (en) Anti-inflammatory pharmaceutical formulations
AR009113A1 (es) UN PRODUCTO ANTICONCEPTIVO PARA DETENER LA OVULACIoN EN MUJERES DURANTE SU PERIODO DE ACTIVIDAD OVÁRICA
DE59914183D1 (de) Abgabeeinrichtung für eine zusammensetzung einer pharmazeutisch wirksamen substanz
MY128759A (en) Oral controlled release formulations
AR011437A1 (es) Composicion farmaceutica para el tratamiento de la migrana y el uso de la misma en la preparacion de un medicamento.
AR012638A1 (es) Uso de pregnan-3-ol-20-onas para la manufactura de un medicamento util para proveer una terapia progestacional
HRP20000704B1 (hr) Peroralni pripravci koji kontrolirano oslobađaju levosimendan
ES2182524T3 (es) Composiciones de hidroxiomeprazol y sus utilizaciones.
DK0742716T3 (da) Farmaceutisk sammensætning til systemisk transdermal indgivelse med det aktive middel morphin-6-glucuronid
DK0927031T3 (da) Farmaceutisk sammensætning indeholdende nimesulid til oral admnistration
BR9710629A (pt) Composi-Æo farmac-utica processo para sua prepara-Æo composto para utiliza-Æo como agente terap-utico e utiliza-Æo e utiliza-Æo de um composto
BR9912260A (pt) Emplastro contendo um sistema terapêutico transdérmico e dose única para ministração
MY145885A (en) Controlled release formulations for oral administration

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1121104

Country of ref document: EP